NZ592823A - Spirocyclic lactams for treating neurodegenerative and/or neurological disorders - Google Patents

Spirocyclic lactams for treating neurodegenerative and/or neurological disorders

Info

Publication number
NZ592823A
NZ592823A NZ592823A NZ59282309A NZ592823A NZ 592823 A NZ592823 A NZ 592823A NZ 592823 A NZ592823 A NZ 592823A NZ 59282309 A NZ59282309 A NZ 59282309A NZ 592823 A NZ592823 A NZ 592823A
Authority
NZ
New Zealand
Prior art keywords
diazaspiro
dec
methyl
formula
compounds
Prior art date
Application number
NZ592823A
Other languages
English (en)
Inventor
Michael Aaron Brodney
Ivan Viktorovich Efremov
Christopher John Helal
Brian Thomas O'neill
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41481076&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ592823(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of NZ592823A publication Critical patent/NZ592823A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ592823A 2008-11-23 2009-11-12 Spirocyclic lactams for treating neurodegenerative and/or neurological disorders NZ592823A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11722508P 2008-11-23 2008-11-23
PCT/IB2009/055043 WO2010058333A1 (en) 2008-11-23 2009-11-12 Lactams as beta secretase inhibitors

Publications (1)

Publication Number Publication Date
NZ592823A true NZ592823A (en) 2012-12-21

Family

ID=41481076

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ592823A NZ592823A (en) 2008-11-23 2009-11-12 Spirocyclic lactams for treating neurodegenerative and/or neurological disorders

Country Status (28)

Country Link
US (1) US20110224231A1 (xx)
EP (1) EP2370439A1 (xx)
JP (2) JP4932065B2 (xx)
KR (1) KR20110086769A (xx)
CN (1) CN102317289A (xx)
AP (1) AP2011005725A0 (xx)
AU (1) AU2009318855A1 (xx)
BR (1) BRPI0922799A2 (xx)
CA (1) CA2743584A1 (xx)
CL (1) CL2011001147A1 (xx)
CO (1) CO6361924A2 (xx)
CR (1) CR20110269A (xx)
CU (1) CU20110113A7 (xx)
DO (1) DOP2011000134A (xx)
EA (1) EA201170722A1 (xx)
EC (1) ECSP11011073A (xx)
GE (1) GEP20135806B (xx)
IL (1) IL212869A0 (xx)
MA (1) MA32929B1 (xx)
MX (1) MX2011005346A (xx)
NI (1) NI201100096A (xx)
NZ (1) NZ592823A (xx)
PE (1) PE20110777A1 (xx)
SV (1) SV2011003916A (xx)
TN (1) TN2011000252A1 (xx)
UA (1) UA99787C2 (xx)
WO (1) WO2010058333A1 (xx)
ZA (1) ZA201103738B (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR074466A1 (es) 2008-12-05 2011-01-19 Sanofi Aventis Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3.
NZ594230A (en) 2009-03-13 2013-11-29 Vitae Pharmaceuticals Inc Inhibitors of beta-secretase
ES2548913T3 (es) 2009-09-11 2015-10-21 Probiodrug Ag Derivados heterocíclicos como inhibidores de glutaminil ciclasa
CN106905215B (zh) 2011-01-25 2021-10-01 拜耳知识产权有限责任公司 制备1-h-吡咯烷-2,4-二酮衍生物的方法
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
TWI557112B (zh) * 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β－分泌酶抑制劑
US9290477B2 (en) 2012-09-28 2016-03-22 Vitae Pharmaceuticals, Inc. Inhibitors of β-secretase
WO2016008064A1 (en) * 2014-07-14 2016-01-21 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
RU2017104110A (ru) * 2014-07-14 2018-08-15 Мерк Шарп И Доум Корп. Ингибиторы внешнего медуллярного калиевого канала почек
WO2016100940A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
EP3233799B1 (en) 2014-12-19 2021-05-19 The Broad Institute, Inc. Dopamine d2 receptor ligands
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase
CN113045484B (zh) * 2019-12-27 2024-01-26 南京药石科技股份有限公司 一种2-氨基-2-(1-甲基-4-哌啶基)丙烷-1-醇的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4876260A (en) * 1987-10-28 1989-10-24 State Of Israel, Israel Institute Of Biological Research Oxathiolanes
US6262066B1 (en) * 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
FR2824901B1 (fr) * 2001-05-21 2003-09-12 Poudres & Explosifs Ste Nale Procede et installation de destruction de fusee montee sur une munition
EP1706116A1 (en) * 2003-12-22 2006-10-04 Schering Corporation Pharmaceutical compositions
CA2554920C (en) * 2004-02-17 2011-12-06 Herm. Sprenger Gmbh & Co. Kg Double-jointed bit for horses
EP1799672B1 (en) * 2004-10-07 2013-01-02 Merck Sharp & Dohme Corp. Cgrp receptor antagonists
CN101068545A (zh) * 2004-10-13 2007-11-07 默克公司 作为β－分泌酶抑制剂用于治疗阿尔茨海默病的螺哌啶化合物
GB0504556D0 (en) * 2005-03-04 2005-04-13 Pfizer Ltd Novel pharmaceuticals
CA2608718A1 (en) * 2005-05-18 2006-11-23 Pfizer Limited 1, 2, 4-triazole derivatives as vasopressin antagonists
WO2007011833A2 (en) * 2005-07-18 2007-01-25 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
EP1940275A4 (en) * 2005-09-20 2014-12-17 Sca Hygiene Prod Ab DONOR
ES2347837T3 (es) * 2006-05-26 2010-11-04 EISAI R&D MANAGEMENT CO., LTD. Compuestos de imidazoazefinona.
CA2651454A1 (en) * 2006-05-26 2007-12-06 Eisai R&D Management Co., Ltd. Imidazoazephinone compounds
WO2007143847A1 (en) * 2006-06-14 2007-12-21 Virochem Pharma Inc. Spirotropane compounds
EP2063889A4 (en) * 2006-09-07 2009-09-16 Merck & Co Inc SPIROPIPERIDINE BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
AU2007307170A1 (en) * 2006-10-06 2008-04-17 Merck & Co., Inc. Macrocyclic spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease
EP2091328B1 (en) * 2006-10-30 2011-12-28 Merck Sharp & Dohme Corp. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease

Also Published As

Publication number Publication date
CL2011001147A1 (es) 2011-09-30
GEP20135806B (en) 2013-04-10
NI201100096A (es) 2011-10-31
JP4932065B2 (ja) 2012-05-16
PE20110777A1 (es) 2011-10-29
EA201170722A1 (ru) 2011-10-31
JP2012509310A (ja) 2012-04-19
TN2011000252A1 (fr) 2012-12-17
MA32929B1 (fr) 2012-01-02
CU20110113A7 (es) 2012-01-31
AU2009318855A1 (en) 2010-05-27
ECSP11011073A (es) 2011-06-30
KR20110086769A (ko) 2011-07-29
US20110224231A1 (en) 2011-09-15
DOP2011000134A (es) 2011-07-31
AP2011005725A0 (en) 2011-06-30
WO2010058333A1 (en) 2010-05-27
JP2012107029A (ja) 2012-06-07
MX2011005346A (es) 2011-06-16
BRPI0922799A2 (pt) 2019-09-24
CR20110269A (es) 2011-07-04
UA99787C2 (xx) 2012-09-25
EP2370439A1 (en) 2011-10-05
CA2743584A1 (en) 2010-05-27
IL212869A0 (en) 2011-07-31
CO6361924A2 (es) 2012-01-20
ZA201103738B (en) 2012-01-25
CN102317289A (zh) 2012-01-11
SV2011003916A (es) 2011-07-28

Similar Documents

Publication Publication Date Title
NZ592823A (en) Spirocyclic lactams for treating neurodegenerative and/or neurological disorders
NZ708183A (en) Mtor kinase inhibitors for oncology indications and diseases associated with the mtor/pi3k/akt pathway
UA106692C2 (uk) ІМІДАЗО[5,1-f][1,2,4]ТРИАЗИНИ ДЛЯ ЛІКУВАННЯ НЕВРОЛОГІЧНИХ РОЗЛАДІВ
EA201270498A1 (ru) 8-этил-6-(арил)пиридо[2,3-d]пиримидин-7(8h)-оны для лечения заболеваний цнс
MX367774B (es) N-ACIL-5,6,7, (8-SUSTITUIDO)-TETRAHIDRO- [1,2,4] TRIAZOLO [4,3-a] PIRAZINAS QUIRALES, NOVEDOSAS, COMO ANTAGONISTAS SELECTIVOS DE RECEPTOR DE NK-3; COMPOSICIÓN FARMACÉUTICA, MÉTODOS PARA USO EN TRASTORNOS MEDIADOS POR RECEPTOR DE NK-3 Y SU SÍNTESIS QUIRAL.
PE20081791A1 (es) Dos derivados ciclicos de oxomorfolina
TW200730525A (en) Therapeutic agents
PH12015500085A1 (en) 5-ht3 receptor antagonists
EP2940017A3 (en) Processes for making compounds useful as inhibitors of atr kinase
PT2945632T (pt) Compostos de heterobiciclo-substituído-[1,2,4]triazolo[1,5-c quinazolin-5-amina adequados para o tratamento ou prevenção de distúrbios do sistema nervoso central
PH12015501145A1 (en) Peptides as oxytocin agonists
EP2650293A8 (en) [1,2,4]triazolo[4,3-b][1,2,4]triazine compound, preparation method and use thereof
EA201890650A1 (ru) ПРОИЗВОДНЫЕ 8-[6-[3-(АМИНО)ПРОПОКСИ]-3-ПИРИДИЛ]-1-ИЗОПРОПИЛ-ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА В КАЧЕСТВЕ СЕЛЕКТИВНЫХ МОДУЛЯТОРОВ КИНАЗЫ МУТАЦИИ АТАКСИИ-ТЕЛЕАНГИЭКТАЗИИ (ATM) ДЛЯ ЛЕЧЕНИЯ РАКА
JP7447128B2 (ja) Ａ２ａ／ａ２ｂ阻害剤としてのピラゾロピリジン及びトリアゾロピリジン
MX2021014016A (es) Un proceso para la fabricacion de (6ar,10ar)-7-propil-6,6a,7,8,9,1 0,10a,11-octahidro-[1,3]dioxolo[4',5':5,6]benzo[1,2-g]quinolina y (4ar,10ar)-1-propil-1,2,3,4,4a,5,10,10a-octahidro-benzo[g]quinoli na-6,7-diol.
KR102426986B1 (ko) 삼환형 화합물 및 포스포다이에스터라제 억제제로서 이의 용도
WO2012044562A3 (en) Pyrazolopyrimidine pde10 inhibitors
WO2012054366A3 (en) Substituted amino-triazolyl pde10 inhibitors
PL2257526T3 (pl) Pochodne spiro (5.5) undekanu
MX2010007742A (es) Preparacion y separacion enantiomerica de 7-(3-piridinil)-1,7-diaz aspiro[4,4]nonano y formas de sal novedosas del racemato y enantiomeros.
EA201171393A1 (ru) 7-([1,2,4]ТРИАЗОЛО[1,5α]ПИРИДИН-6-ИЛ)-4-(3,4-ДИХЛОРФЕНИЛ)-1,2,3,4-ТЕТРАГИДРОИЗОХИНОЛИН И ЕГО ПРИМЕНЕНИЕ
UA102845C2 (xx) ТЕТРАГІДРО-ПІРАЗОЛО$1,5-a]ПІРИДО-ПІРИМІДИНИ - АНТАГОНІСТИ СЕРОТОНІНОВИХ 5-HT6 РЕЦЕПТОРІВ ТА ЇХ ЗАСТОСУВАННЯ$ТЕТРАГИДРО-ПИРАЗОЛО$1,5-a]ПИРИДО-ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТ6 РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ
TN2012000191A1 (en) Quinuclidine compounds as alpha-7nicotinic acetylcholine receptor ligands
MY165623A (en) 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
WO2014150114A8 (en) Substituted pyridizinone derivatives as pde10 inhibitors

Legal Events

Date Code Title Description
PSEA Patent sealed
LAPS Patent lapsed